Evidence map›Paper›PMID 26350511›Full record

ArticleEuropean journal of human genetics : EJHG2016

Phenotypic extremes in rare variant study designs.

Gina M Peloso, Daniel J Rader, Stacey Gabriel, Sekar Kathiresan, Mark J Daly, Benjamin M Neale

Open access · bronzeAbstract read
In one paragraph

Article in European journal of human genetics : EJHG, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 2 pooled it
5.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 2 syntheses or guidelines pooled it, 66 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Stroke · 2025
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. A state-based approach to genomics for rare disease and population screening.Genetics in medicine : official journal of the American College of Medical Genetics · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Gina M PelosoCenter for Human Genetic Research, Massachusetts General Hospital, Boston, MA, USA.
Daniel J RaderDivision of Translational Medicine and Human Genetics, University of Pennsylvania, Philadelphia, PA, USA.
Stacey GabrielProgram in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Sekar KathiresanCenter for Human Genetic Research, Massachusetts General Hospital, Boston, MA, USA.
Mark J DalyCenter for Human Genetic Research, Massachusetts General Hospital, Boston, MA, USA.
Benjamin M NealeCenter for Human Genetic Research, Massachusetts General Hospital, Boston, MA, USA.
Massachusetts General Hospital · USBroad Institute · USCenter for Human Genetics · USUniversity of Pennsylvania · US

Funding

MULTIDISCIPLINARY RESEARCH TRAINING IN CARDIOLOGYT32HL007208 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI Patrick Thomas Ellinor, David E Sosnovik · 1985 to 2026
$16.1M
Statistical methods for studies of rare variantsR01MH101244 · NIMH · HARVARD MEDICAL SCHOOL · PI Benjamin Michael Neale, ALKES L PRICE · 2013 to 2026
$9.4M
Discovery of Mendelian Dyslipidemia and Heart Attack Genes Using Exome SequencingR01HL107816 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI KATHIRESAN, SEKAR · 2011 to 2015
$2.7M
Discovering lipoprotein lipase pathway variants that protect against CHDK01HL125751 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI PELOSO, GINA MARIE · 2015 to 2018
$562k
NHLBI NIH HHS K01 HL125751NHLBI NIH HHS R01 HL107816NHLBI NIH HHS T32 HL007208NIMH NIH HHS R01 MH101244
6 · The paper itself

Abstract

Currently, next-generation sequencing studies aim to identify rare and low-frequency variation that may contribute to disease. For a given effect size, as the allele frequency decreases, the power to detect genes or variants of interest also decreases. Although many methods have been proposed for the analysis of such data, study design and analytic issues still persist in data interpretation. In this study we present sequencing data for ABCA1 that has known rare variants associated with high-density lipoprotein cholesterol (HDL-C). We contrast empirical findings from two study designs: a phenotypic extreme sample and a population-based random sample. We found differing strengths of association with HDL-C across the two study designs (P=0.0006 with n=701 phenotypic extremes vs P=0.03 with n=1600 randomly sampled individuals). To explore this apparent difference in evidence for association, we performed a simulation study focused on the impact of phenotypic selection on power. We demonstrate that the power gain for an extreme phenotypic selection study design is much greater in rare variant studies than for studies of common variants. Our study confirms that studying phenotypic extremes is critical in rare variant studies because it boosts power in two ways: the typical increases from extreme sampling and increasing the proportion of relevant functional variants ascertained and thereby tested for association. Furthermore, we show that when combining statistical evidence through meta-analysis from an extreme-selected sample and a second separate population-based random sample, power is lower when a traditional sample size weighting is used compared with weighting by the noncentrality parameter.

Indexed as

MutationPhenotypeATP Binding Cassette Transporter 1BiasGenome-Wide Association StudyHumansMeta-Analysis as TopicModels, GeneticSample SizeABCA1 protein, humanATP Binding Cassette Transporter 1

Identifiers

PMID26350511
PMCPMC4867440
OpenAlexW1450941878

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.